Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Busy address KBO
70 other companies have their registered office at the same address; threshold 10.
-
Not on Peppol Peppol
Not registered in the Peppol network, mandatory for VAT-liable companies since 1 January 2026.
Financials
Financial year 2025
KBC Private Partners Life Sciences from Sint-Jans-Molenbeek, company number BE0769268594, closed financial year 2025 with a result of € 1.7 million after tax. For that financial year KBC Private Partners Life Sciences recorded a gross margin of € -480,002 and equity of € 29.9 million. Compared with financial year 2024, the result moved from € 1.4 million to € 1.7 million. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 26, 2026.
€ 29.9 million
▲ 20% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 1.7 million
▲ 20% vs 2024
Profit after tax over the fiscal year.
€ 3.6 million
▲ 35% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 2.5 million.
People and assets in 2025
0
Average over the fiscal year, from the social balance sheet.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 23,400
▼ 25% vs 2024
Supplier invoices still open on the last day of the fiscal year.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € -536,243 | € -459,875 | € -459,328 | € -480,002 | ▼ € 20,674 |
| Profit after taxes | € -858,850 | € 291,038 | € 1,405,194 | € 1,692,201 | ▲ 20% |
| Equity | € 16,724,484 | € 28,737,744 | € 24,891,783 | € 29,908,896 | ▲ 20% |
| Total debts | € 22,404 | € 19,362 | € 31,264 | € 23,418 | ▼ 25% |
| Cash | € 5,414,758 | € 13,155,624 | € 2,674,745 | € 3,604,851 | ▲ 35% |
| Retained profit | € -858,850 | € -567,812 | € 837,382 | € 2,529,583 | ▲ 202% |
| Balance sheet total | € 16,746,888 | € 28,757,106 | € 24,923,047 | € 29,932,314 | ▲ 20% |
Key figures of KBC Private Partners Life Sciences, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to KBC Private Partners Life Sciences?
What happened at KBC Private Partners Life Sciences in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 1.7 million (▲ 20% vs 2024). Source: NBB ↗
- New establishment in Sint-Jans-Molenbeek. KBO
- Start of the company according to the CBE. KBO
- KBC SECURITIES NV became a director. NBB
In short
From € 858,850 loss in 2022 to € 1.7 million profit in 2025.
Paid € 89,928 in corporate taxes since 2022.
Best year ever: 2025, with € 1.7 million profit.
A new publication or filing at KBC Private Partners Life Sciences? We notify you, reason included.
Follow KBC Private Partners Life SciencesDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of KBC Private Partners Life Sciences (Privak) comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
KBC Private Partners Life SciencesBehind KBC Private Partners Life Sciences is KBC SECURITIES NV. The shares are held by KBC Private Partners Life Sciences (Privak) (47.9%).
Directors
According to the 2025 annual accounts
Director · represented by Isabelle Cardinael
Also active at: POZYX, SYMPL, ArtiQ, Pharrowtech, KBC Private Partners Life Sciences (Privak), EXALATE, FLANDERSBIO, VENTORY +2 more
since 2021
Shareholders
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Havenlaan 2
1080 Sint-Jans-Molenbeek
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 70 companies are registered at this address.
All companies at this address →KBC Groep
€ 107.5 million revenue · 2025
KBC Commercial Finance
€ 37.9 million revenue · 2025
Immobilière Sinte-Goedele
ALMAFIN REAL ESTATE
€ 1.8 million revenue · 2025
Immolease-Trust
€ 1.1 million revenue · 2025
+65 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0769.268.594
- VAT number
- BE 0769.268.594
- Registered office
- Havenlaan 2, 1080 Sint-Jans-Molenbeek
- Names & denominations
- KBC Private Partners Life Sciences
- Enterprise type
- Rechtspersoon
- Legal form
- Limited partnership
- Legal situation
- Normale toestand
- Start date
- 2 June 2021
- Peppol
- Not registered